Every Form 4 that Candel Therapeutics, Inc. (CADL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CADL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CADL filings page.
Candel Therapeutics, Inc. (CADL) reported that Chief Executive Officer and director Paul Peter Tak exercised options and sold shares of common stock. On September 10, 2026, he exercised options to acquire 125,000 shares at $1.55 per share, and on the same day sold 220,866 shares at a weighted average price of $11.4997 per share in multiple trades. On September 11, 2026, he sold an additional 59,379 shares at a weighted average price of $10.4564 per share in multiple trades. The option exercise related to an award expiring on October 10, 2030, and following that exercise 1,638,968 option-linked shares remained outstanding. All reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026 and modified on June 11, 2026.
Candel Therapeutics, Inc. (CADL) reported that director Martine Zimmermann received a grant of stock options covering 64,000 shares of Common Stock on September 8, 2026. The options have an exercise price of $12.60 per share and expire on September 8, 2036. The award vests in thirty-six equal monthly installments, subject to her continued service, and represents her direct beneficial ownership of these derivative securities. No Rule 10b5-1 trading plan is reported for this grant.
Candel Therapeutics, Inc. (CADL) reported that Chief Technology Officer Tyagarajan Seshu sold 7,000 shares of common stock at $12.00 per share on 2026-08-17 in an open-market or private transaction. Following this sale, Seshu directly held 76,865 shares of Candel Therapeutics common stock. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on 3/16/2026.
Candel Therapeutics Chief Commercial Officer Mark E. Sims received a grant of stock options covering 285,000 shares of common stock. The options have an exercise price of $10.03 per share and expire on July 6, 2036. Twenty-five percent vest on July 6, 2027, with the remainder vesting in 36 equal monthly installments, contingent on continued service.
Candel Therapeutics Chief Scientific Officer Francesca Barone sold 23,447 shares of common stock in an open-market transaction at a weighted average price of $10.0554 per share on June 29, 2026. The sale was executed under a Rule 10b5-1 trading plan adopted on March 16, 2026, and Barone now directly holds 77,362 shares.
Candel Therapeutics, Inc. Chief Technology Officer Tyagarajan Seshu reported an open-market sale of 7,000 shares of common stock at a weighted average price of $10.0216 per share on June 29, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 16, 2026.
After this transaction, Seshu directly holds 83,865 shares of Candel Therapeutics common stock. The price reflected a range of individual trades between $10.00 and $10.07 per share.
Candel Therapeutics director Paul B. Manning received a grant of stock options as compensation. He was awarded options to buy 2,199 shares of common stock at an exercise price of $10.30 per share. The award replaces normal quarterly cash payments and is fully vested at the time of grant, leaving him with 2,199 derivative securities after this transaction.
Candel Therapeutics director Joseph C. Papa received a new stock option award as part of his board compensation. The grant covers 1,331 options to buy common stock at an exercise price of $10.30 per share.
The award was granted in lieu of normal quarterly cash payments and is fully vested at the time of grant, so Papa can exercise all 1,331 options any time until their expiration if he chooses.
Candel Therapeutics director Nicoletta Loggia received a grant of stock options as compensation. The award covers 381 options to buy Candel common stock at an exercise price of $10.30 per share, expiring on June 30, 2036. According to the disclosure, this award was granted in lieu of normal quarterly cash payments and is fully vested at the time of grant. Following the grant, Loggia holds 381 stock options directly.
Candel Therapeutics, Inc. director Radhakrishnan Maha received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.
The option is subject to time-based vesting. All 32,000 underlying shares vest and become exercisable on the earlier of June 23, 2027 or the date of the company’s next annual stockholder meeting, with vesting ending if the director leaves the board unless the board decides otherwise.
Candel Therapeutics director Nicoletta Loggia received a grant of stock options to buy 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036. Following this grant, she holds options covering 32,000 shares.
The award is subject to time-based vesting. The options vest and become exercisable on the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders, with vesting stopping if she leaves the board unless the board decides otherwise.
Candel Therapeutics director Joseph C. Papa received a grant of stock options, giving him the right to buy 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.
The award is subject to time-based vesting. All 32,000 underlying shares vest and become exercisable on the earlier of June 23, 2027 or the date of the next annual meeting of stockholders, as long as he continues serving on the board. Following this grant, he holds 32,000 stock options directly.
Candel Therapeutics director Edward J. Benz Jr. received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.
The award is subject to time-based vesting, becoming exercisable on the earlier of June 23, 2027 or the next Annual Meeting of Stockholders, as long as he continues serving on the board unless the board decides otherwise. Following this grant, he holds 32,000 stock options directly.
Candel Therapeutics director Christopher Martell received a grant of stock options for 32,000 shares of Common Stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.
The award is subject to time-based vesting and will vest and become exercisable on the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders, with vesting ceasing if he leaves the board unless the board decides otherwise. After this grant, he holds 32,000 options directly.
Candel Therapeutics director Renee Gaeta received a grant of 32,000 stock options to buy common shares at an exercise price of $9.08. These options were awarded as compensation, not through open-market trading.
The options use time-based vesting and become exercisable on the earlier of June 23, 2027 or the company’s next Annual Meeting of Stockholders, with vesting stopping if she leaves the board unless the board decides otherwise. The options expire on June 23, 2036, and following this grant she holds 32,000 options directly.
Candel Therapeutics director Gary J. Nabel received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036. These options are subject to time-based vesting and will vest and become exercisable on the earlier of June 23, 2027 or the date of the company’s next annual meeting of stockholders. Vesting stops if he ceases serving on the board, unless the board determines that vesting should continue.
Candel Therapeutics director Diem Nguyen received a stock option grant for 32,000 shares of common stock. The options have an exercise price of $9.0800 per share and expire on June 23, 2036. They vest upon the earlier of June 23, 2027 or the company’s next annual stockholder meeting, so long as Nguyen continues serving on the board.
Candel Therapeutics director Paul B. Manning received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036. Following this award, he holds 32,000 stock options directly.
The option is subject to time-based vesting. The underlying shares vest and become exercisable on the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders, and vesting stops if he leaves the board unless the board determines otherwise.
Candel Therapeutics director Paul B. Manning received a stock option grant covering 4,618 shares of Common Stock. The options have an exercise price of $4.90 per share, were fully vested at the time of grant, and expire on March 31, 2036. According to the filing, this award was given in lieu of normal quarterly cash payments, and following the grant he holds options for 4,618 shares directly.
Candel Therapeutics director Joseph C. Papa received a grant of 2,795 stock options as compensation. The options were awarded on March 31, 2026 with an exercise price of $4.90 per share and relate to 2,795 shares of common stock.
This award was granted in lieu of normal quarterly cash payments and is fully vested at the time of grant. Following this grant, Papa holds 2,795 derivative securities directly, and the options are scheduled to expire on March 31, 2036.
Candel Therapeutics director Nicoletta Loggia received a fully vested stock option award covering 779 shares of common stock. The option has an exercise price of $4.90 per share and was granted in lieu of normal quarterly cash payments, leaving her with 779 derivative securities following the grant.
Candel Therapeutics director Paul B. Manning, through The Paul B. Manning Revocable Trust, completed an open-market purchase of 550,458 shares of common stock at $5.45 per share. After this transaction, indirect holdings include shares in the Trust and in BKB Growth Investments, LLC, plus additional shares held directly and jointly with his spouse.
Candel Therapeutics Chief Technology Officer Seshu Tyagarajan received a new stock option grant. On January 26, 2026, he was granted options to purchase 154,000 shares of Candel Therapeutics common stock at an exercise price of $6.01 per share.
The options vest in forty-eight equal monthly installments starting after January 26, 2026, as long as he continues to serve the company on each vesting date. After this grant, he beneficially owns 154,000 stock options directly.
Candel Therapeutics Chief Medical Officer William Garrett Nichols received a stock option award reported on a Form 4. On January 26, 2026, he was granted an option to buy 136,500 shares of Candel common stock at an exercise price of $6.01 per share.
The option vests in 48 equal monthly installments following January 26, 2026, contingent on his continued service. The option expires on January 26, 2036. After this grant, Nichols directly beneficially owns 136,500 derivative securities linked to Candel common stock.
Candel Therapeutics, Inc. reported a new stock option grant to its Chief Financial Officer, Charles Schoch. On January 26, 2026, he received options to purchase 232,000 shares of common stock at an exercise price of $6.01 per share.
These options vest over time. The underlying shares will vest and become exercisable in forty-eight equal monthly installments following January 26, 2026, and each installment depends on his continued service with the company on the relevant vesting date.
Candel Therapeutics, Inc. reported that its Chief Executive Officer and director, Paul Peter Tak, received a grant of stock options. On January 26, 2026, he was awarded an option to purchase 629,000 shares of common stock at an exercise price of $6.01 per share.
The option was granted directly to him and is subject to time-based vesting. The underlying shares vest in 48 equal monthly installments starting after January 26, 2026, contingent on his continued service with the company on each vesting date. Following this grant, he beneficially owned stock options for 629,000 shares.
Candel Therapeutics Chief Scientific Officer granted stock options
Candel Therapeutics’ Chief Scientific Officer, Francesca Barone, received a stock option to buy 232,000 shares of common stock at an exercise price of $6.01 per share. The option was granted on January 26, 2026 and expires on January 26, 2036.
The option vests over time rather than all at once. The shares underlying the option vest and become exercisable in 48 equal monthly installments following January 26, 2026, as long as Barone continues serving the company on each vesting date. After this grant, she beneficially owns 232,000 stock options directly.